Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$1.15
EPS est.
$0.97
EPS surprise
+18.56%
1-day move
-6.60%
Indivior's earnings report showed a strong beat on EPS, which indicates better-than-expected profitability. However, the stock fell by 6.6%, likely due to the lack of revenue information and guidance, leaving investors uncertain about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.15 | $1.12 | +18.56% |
| Revenue | N/A | $329M | N/A |
No transcript is on record, so the analysis is based solely on numerical results.
Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for addiction and related disorders. With a market cap of $5 billion, it plays a crucial role in addressing the growing global opioid crisis and mental health issues.
Last quarter
In Q1-2026, Indivior reported an EPS of $0.96, significantly exceeding expectations of $0.64, showcasing strong operational performance. The stock reacted positively, gaining 7.70% the following day.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
100%
Avg EPS surprise
+58.43%
Avg 1-day reaction
+6.57%
Analysts are generally optimistic about Indivior's upcoming earnings, with expectations for another strong performance given recent trends. The consensus EPS estimate reflects confidence in the company's ability to maintain growth.
Bull case
If Indivior beats EPS estimates again, it could signal robust demand for its products and further validate its growth strategy, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company misses expectations, it may raise concerns about its market position and ability to sustain growth, leading to a negative reaction from investors.
Key metrics to watch
EPS
$1.12Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$329MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $1.12?
A beat on EPS would reinforce the company's growth trajectory and could lead to a positive stock reaction.
Q2
What are the revenue expectations for the upcoming quarter?
Revenue performance is critical for assessing market demand and the effectiveness of the company's strategies.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.2%
Why consensus could be wrong
The consensus may underestimate the impact of recent product launches and market expansion efforts, which could drive higher-than-expected revenue.
Supporting evidence
Indivior has consistently beaten EPS estimates in the past four quarters, indicating strong operational execution.
The company's focus on innovative treatments positions it well in a growing market, potentially leading to increased sales.
Options pricing suggests that traders expect significant movement, which may not align with the consensus view.
Key risk
If revenue exceeds $332M, it could challenge the current market expectations and lead to a reevaluation of growth potential.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will indicate whether Indivior can maintain its growth momentum in a competitive market.
Bull confirmed if
An EPS of $1.15 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $1.09 would raise concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±20.61%
Historical Avg
±9.2%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±20.6% while INDV has averaged ±9.2% over the last 5 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
36.0%
Smart-money positioning from the most recent 13F filings.
Institutional
102.97%
of float
Insider
1.80%
of float
Holders
457
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
18,709,432 sh · $676.0M
15.85%
0.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Indivior beats expectations, history suggests the stock could rise by around 9.86%, confirming strong growth potential.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 9.86%.
The lines on the call that would change the story.
Vanguard Portfolio Management LLC
7,572,287 sh · $273.6M
6.42%
-4.0%
Oaktree Capital Management LP
6,127,212 sh · $221.4M
5.19%
-12.3%
Vanguard Capital Management LLC
5,495,486 sh · $198.6M
4.66%
-1.6%
State Street Corporation
4,992,071 sh · $180.4M
4.23%
1.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.